Modality
siRNA
MOA
USP1i
Target
LAG-3
Pathway
NF-κB
PTSD
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
~Jul 2023
→ ~Oct 2024
Phase 3
Jan 2025
Phase 3Current
NCT06829060
1,673 pts·PTSD
2025-01→TBD·Completed
1,673 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2025
P3
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06829060 | Phase 3 | PTSD | Completed | 1673 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |